

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11) Publication number:

0 104 860**A1**

(12)

EUROPEAN PATENT APPLICATION(21) Application number: **83305484.4**(22) Date of filing: **19.09.83**(51) Int. Cl.³: **C 07 D 209/34****C 07 D 401/04, C 07 D 403/04****C 07 D 403/06, A 61 K 31/40****A 61 K 31/415, A 61****K 31/445****A 61 K 31/535**(30) Priority: **20.09.82 US 420544**(43) Date of publication of application:
04.04.84 Bulletin 84/14(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE(71) Applicant: **PFIZER INC.**
235 East 42nd Street
New York, N.Y. 10017(US)(72) Inventor: **Howard, Harry R.**
272 West Woods Terrace
Bristol, CT 06010(US)(72) Inventor: **Sarges, Reinhard**
River Road
Mystic, CT 06355(US)(74) Representative: **Moore, James William**
Pfizer Limited Ramsgate Road
Sandwich Kent CT13 9NJ(GB)(54) **1-Phenyl-2(1H,3H)-indolone psycho-therapeutic agents.**

(57) Certain substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones are highly potent gabaergic agents, valuable in the treatment of individuals suffering from schizophrenia or reversing the side effects of a previously or concurrently administered neuroleptic agent; or in the treatment of epilepsy. A wider class of substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones, together with 1-phenyl-3-(2-pyrrolidinylidene)-2(1H,3H)-indolones, and homologs thereof, are valuable in the treatment of anxiety.


EP 0 104 860 A1

1-PHENYL-2(1H,3H)-INDOLONE PSYCHO-
THERAPEUTIC AGENTS

Certain novel, 1-phenyl-3-[aminoalkylidene or di(loweralkyl)aminoalkylidene]-2(1H,3H)-indolones, specifically substituted on phenyl with at least one alkyl, alkoxy, alkylthio, chloro, fluoro or trifluoromethyl group, are potent gabaergic agents, valuable in the treatment of schizophrenia per se, as well as in reversing or avoiding side effect of oral-facial dyskinesia (tardive dyskinesia), commonly seen in schizophrenic individuals under present or past treatment with a neuroleptic agent. The present invention encompasses these novel gabaergic agents, together with pharmaceutical compositions thereof, and use thereof in treating schizophrenia or reversing the side effects of a previously or concurrently administered neuroleptic agent. Most of these compounds also have valuable anxiolytic activity, as detailed below.

More broadly, the present invention encompasses variously substituted 1-phenyl-3-[aminoalkylidene-, lower alkylaminoalkylidene- and di(loweralkyl)aminoalkylidene]-2(1H,3H)-indolones (some of which are known compounds), novel 1-phenyl-3-(piperidino-, pyrrolidino-, morpholino- or imidazolo-alkylidene)-2(1H,3H)-indolones and novel 1-phenyl-3-(2-pyrrolidinylidene, 2-piperidinylidene, or 2-perhydroazepinylidene, optionally substituted on nitrogen with lower alkyl, phenyl or benzyl)-2(1H,3H)-indolones. These three classes of compounds are anxiolytic agents, valuable in the treatment of hyperanxious individuals. The present invention is thus also directed to the above two novel classes of compounds and pharmaceutical compositions thereof, and to the use of all three classes of compounds in the treatment of anxiety in hyperanxious individuals.


Belgian Patent 849,626 broadly discloses compounds of the formula



which include m as 1, 2 or 3 and R^a and R^b each as H, OH, lower alkyl, lower alkoxy, F, Cl, Br, NO_2 , NH_2 or $\text{C}_6\text{H}_5\text{CH}_2$.

These compounds are not disclosed as having pharmaceutical utility per se, but rather are indicated to be chemical intermediates. The only compound of this class isolated and characterized is the compound wherein $R^a = R^b = \text{H}$. The latter compound, like at least two dozen other compounds of this class, does not possess MPA (3-mercaptopropionic acid) induced convulsion inhibitory activity ("gabaergic" activity). However, from among the many thousands of possible compounds defined by the Belgian patent, we have surprisingly found that a few, defined by the formula (I) below have gabaergic activity and so are useful in the treatment of schizophrenic individuals.

The present invention is concerned in part with compounds of the formula



--- (I)

wherein: A is hydrogen or methyl;

R is hydrogen or (C_1-C_2) alkyl;

X is hydrogen, (C_1-C_2) alkyl, (C_1-C_2) alkoxy, (C_1-C_2) alkylthio; chloro, fluoro or trifluoromethyl;

Y is hydrogen, (C_1-C_2) alkyl, (C_1-C_2) alkoxy or (C_1-C_2) alkylthio; and

Z and Z^1 are each independently hydrogen or methyl;

with the provisos that:

at least one of X, Y, Z and Z^1 is other than hydrogen; and


at least one of X and Y is other than (C_1-C_2) -alkoxy.

Based on their excellent gabaergic activity as well as ease of preparation, one group of preferred compounds of the formula (I) have Z and Z^1 as hydrogen, with X as chloro and Y as hydrogen. The most preferred compounds in this subclass have A as hydrogen, with R as hydrogen, methyl or ethyl, or both A and R as methyl. A second group of preferred compounds of the formula (I) not only have Z and Z^1 as hydrogen, but also A and Y as hydrogen. The most preferred compounds in this subclass have X as (C_1-C_2) alkyl, trifluoromethyl, methoxy or fluoro. A third subclass of preferred compounds also have Z and Z^1 as hydrogen, with R as methyl and Y as methoxy. Preferred compounds in this subclass have X as chloro with A as hydrogen or methyl, or X as fluoro with A as hydrogen. In the two additional most preferred compounds, one has A and Z^1 as hydrogen, R and Z as methyl, X as chloro and Y as methoxy; and the other has A, X, Y and Z as hydrogen, and R and Z^1 as methyl.

-4-

The present invention also encompasses pharmaceutical compositions suitable for the treatment of a person suffering from schizophrenia which comprise a pharmaceutically-acceptable carrier and a compound of the formula (I) in an amount which will alleviate said schizophrenia or reverse the side effects of a neuroleptic agent simultaneously or previously administered in the treatment of said schizophrenia; and a method of treating a person suffering from schizophrenia which comprises administration to said person a compound of the formula (I) in an amount sufficient to alleviate said schizophrenia or reverse the side effects of a neuroleptic agent simultaneously or previously used in the treatment of said schizophrenia.

The present invention also encompasses compounds of the formula



---(II)

wherein,

in a first alternative,

A^1 is hydrogen or methyl; and
B and C together with the nitrogen atom to which they are attached, form a piperidine, pyrrolidine, morpholine or imidazole ring;
or

in a second alternative,

A^1 and B together are 1,3-propylene, 1,4-butylene or 1,5-pentylene; and C is hydrogen, (C_1-C_2) alkyl, phenyl or benzyl;


W is hydrogen, (C₁-C₂)alkyl, chloro, fluoro or (C₁-C₂)alkoxy; and W¹, X¹ and Y¹ are each independently hydrogen, (C₁-C₂)alkyl, (C₁-C₂)alkoxy, (C₁-C₂)alkylthio, bromo, chloro, fluoro, trifluoromethyl, hydroxy, formyl, carboxamido, (C₁-C₂)alkylcarboxamido, di(C₁-C₂)alkylcarboamido, cyano, nitro, amino, (C₁-C₂)alkylamino or di(C₁-C₂)alkylamino.

Based on their excellent anxiolytic activity, as well as their ease of preparation, preferred compounds of the formula (II) wherein A¹, B and C are in the first alternative have A¹, W, W¹ and Y¹ as hydrogen. A first more preferred group has, X¹ as chloro. Most preferred compounds in this subclass are those wherein B and C taken together with the nitrogen to which they are attached, form either a pyrrolidine or a morpholine ring. A second more preferred group have X¹ as hydrogen, most preferably those wherein B and C taken together with the nitrogen to which they are attached, form an imidazole ring.

With reference to compounds of the formula (II) wherein A¹, B and C are in the second alternative, one preferred class of compounds has A¹ and B taken together as 1,3-propylene, more preferably with C as methyl and W¹ as hydrogen. Most preferred compounds in this subclass have W and Y¹ as hydrogen and X¹ as 3-methoxy; W as hydrogen, X¹ as hydrogen or 3-chloro and Y¹ as 4-methoxy; or W as 6-chloro and X¹ and Y¹ as hydrogen. A second preferred class have W, W¹ and Y¹ as hydrogen with X¹ as 3-chloro. Most preferred compounds in this subclass have A¹ and B as 1,3-propylene and C as benzyl or methyl; or A¹ and B as 1,4-butylene and C as methyl.

-6-

Finally, the present invention encompasses a compound of the following formula (III) for use as a therapeutic agent, particularly for treating anxiety in a hyperanxious person.



---(III)

wherein

in a first alternative

A^2 is hydrogen or methyl, and

B^1 and C^1 are each independently hydrogen, (C_1-C_2) alkyl, phenyl or benzyl;

in a second alternative

A^2 is hydrogen or methyl, and

B^1 and C^1 together with the nitrogen atom to which they are attached, form a piperidine, pyrrolidine, morpholine or imidazole ring;

in a third alternative

A^2 and B^1 together are 1,3-propylene, 1,4-butylene or 1,5-pentylene, and C^1 is hydrogen, (C_1-C_2) alkyl, phenyl or benzyl;

W is hydrogen, (C_1-C_2) alkyl, (C_1-C_2) alkoxy, chloro or fluoro; and

W^1 , X^1 and Y^1 are each independently hydrogen, (C_1-C_2) alkyl, (C_1-C_2) alkoxy, (C_1-C_2) alkylthio, bromo, chloro, fluoro, trifluoromethyl, hydroxy, formyl, carbox-amido, (C_1-C_2) alkylcarboxamido, di (C_1-C_2) alkylcarbox-amido, cyano, nitro, amino, (C_1-C_2) alkylamino or di (C_1-C_2) alkylamino;


with the proviso that when A^2 is hydrogen or methyl, B^1 and C^1 are each independently hydrogen, (C_1 - C_2)alkyl, phenyl or benzyl, and any one of W^1 , X^1 and Y^1 is 4-chloro, at least one of W^1 , X^1 and Y^1 is other than hydrogen.

It will be noted that when the compounds of the formula (III) are in the first alternative, most of the compounds of the formula (I) fall within the scope thereof. In said first alternative, a first group of compounds preferred for anxiolytic use have A^2 , W , W^1 , and Y^1 as hydrogen, and B^1 and C^1 as methyl. Most preferred compounds with this subclass have X^1 as 3-chloro, 3-methoxy, 3-fluoro, 3-methyl or 3-cyano. A second preferred group within this first alternative has A^2 , W and W^2 as hydrogen, Y^1 as 4-methoxy and B^1 and C^1 as methyl; most preferably, X^1 as chloro or fluoro.

Compounds of the formula (III) in the second and third alternatives fully correspond to compounds of the formula (II) as defined above, so that preferred use of these compounds fully corresponds to preferred compounds as detailed above.

Compounds of the present invention are readily prepared by a variety of Methods A to H, as detailed below.

Method A - Reaction of an Amide Dialkylacetal
with a 1-Phenyl-2(1H,3H)-indolone:



herein A and R are as previously defined (except that
 5 generally R will be other than hydrogen), R¹ is (C₁-
 C₃)alkyl, and aromatic rings are appropriately sub-
 stituted according to the formulae (I), (II) and
 (III).


Because of the ready availability of the required
 10 amide dimethyl acetals, this is one of the preferred
 methods when R is methyl. The reaction is usually
 carried out in the presence of a reaction-inert solvent
 or diluent (i.e., a solvent which does not interact
 with starting materials, reagents or product to sig-
 15 nificantly depress yield of the desired product).
 Chloroform is the preferred solvent. Temperature is
 not critical, although it is usually elevated (50-
 100°C.) to assure that reaction will occur at a reason-
 able rate. The reflux temperature of chloroform is
 20 particularly convenient, when the latter is used as
 solvent. At least one equivalent of the amide acetal
 is used, in order to maximize yield based on the

indolone. Use of a slight excess of the acetal is helpful in assuring complete conversion of the indolone within a reasonable time. Product is generally isolated by evaporation, and is optionally purified by chromatography and/or crystallization.

The starting indolones required for syntheses according to Method A are generally available by cyclization of an appropriately substituted N-phenyl-alpha-haloacetanilide (Method J, below), in turn made by alpha-haloacetylation of the appropriately substituted diphenylamine (Method K, below); by basic hydrazine hydrate reduction of the corresponding isatin, in turn made from the appropriately substituted diphenylamine and oxalyl chloride (see Preparation M1 and M2 below); or halogenation/hydrolysis of appropriately substituted 1-arylimdoles (Method L, below), in turn made by arylation of indole (Method C, below).

The aromatic halides required for these and other syntheses described below are available commercially or by literature methods; for example, m-iodoethylbenzene by diazotization/KI treatment of m-ethyl-aniline (Ann. 714:109, 1968); p-bromo-o-fluoroanisole by bromination of o-fluoroanisole (J. Prakt. Chem. 143: 18-28, 1935); o-chloro-p-iodoanisole by chlorination of p-iodoanisole (J. Chem. Soc. 1931:1121-1123); alkylation of appropriately substituted phenols (see Preparation E2 below). Required diphenylamines are likewise available commercially; by literature methods, e.g., di-(4-methoxyphenyl)amine by an improved Ullman procedure (J. Org. Chem. 26:2721, 1961); or by the arylation/hydrolysis of acetanilides (see Method C, Preparation C45, below).

Method B - Reaction of an Amide, Activated by
POCl₃, with a 1-Phenyl-2(1H,3H)-indolone:




wherein A², B¹ and C¹ are as previously defined and
5 aromatic rings are appropriately substituted according
to the formulae (I), (II) and (III).

The procedure of Method B is essentially that
used in Belgian Patent 849,626 at pages 11-12 for the
preparation of 1-phenyl-3-(dimethylaminomethylene)-2-
10 (1H,3H)-indolone from the 1-phenylindolone and di-
methylformamide. The amide, usually in the presence
of a reaction-inert diluent (as defined above), such
as toluene, is reacted with the phosphorous oxychloride
at 0-30°C. for a short period of time (10-30 minutes).
15 There should generally be at least one mole of amide
per mole of POCl₃; usually an excess (up to 2.5 moles)
of the amide is used. The appropriately substituted
1-phenyl-2(1H,3H)-indolone (usually about 0.67 to 1
mole/mole of POCl₃) is added and the reaction warmed
20 at 50-100°C. until reaction is substantially complete.
At 65-70°C., a reaction time of 16-18 hours is generally
suitable.

Alternatively, an iminoether is used as the activated form of an amide derived from NH_3 or a primary amine. The iminoether is reacted directly with the 1-phenyl-2(1H,3H)-indolone in a reaction-inert solvent, generally at elevated temperature (75-125°C.); cf Example M1-M3 below. The iminoethers are prepared by standard methods, e.g., the well known reaction of triethyloxonium fluoroborate with the amide.

The amides required for the present syntheses are available commercially or by reaction of a secondary amine with acetate or formate ester, acetic or formic acid or an activated form thereof such as acetyl chloride, acetic anhydride or acetoformic acid reagent; or by cyclization of suitable omega-amino acids or their derivatives. The required 1-phenyl-2(1H,3H)-indolones are synthesized as described above.

Method C - Arylation of 3-Substituted-(1H,3H)-Indolones



wherein A^2 , B^1 and C^1 are as hereinbefore defined (except that generally both B^1 and C^1 are other than

hydrogen), X is iodo or bromo, and aromatic rings are appropriately substituted according to the formulae (I), (II) and (III).

5 The first stage of the procedure of Method C is generally conversion of the starting indolone to its alkali metal salt, preferably done with a molar equivalent of a reagent such as NaH, which forms the required salt irreversibly. Salt formation is preferably carried out in a solvent, one which is reaction-
10 inert, as defined above; dry dimethylformamide is well-suited for this purpose. Temperature is not critical but ambient temperatures (e.g., 15-30°C.) are usually well-suited, avoiding the expense of heating or cooling. Salt formation is rapid and, with NaH as reagent, is
15 judged complete when evolution of hydrogen ceases. The aromatic bromide or iodide (usually at least one molar equivalent, but optionally with up to 2 molar equivalents in excess to assure complete conversion of the starting indolone) and cuprous bromide (Cu_2Br_2 , usually
20 substantially one mole/mole of indolone) are added, and the reaction mixture heated to elevated temperatures (100-200°C.) until the reaction is substantially complete. A reaction time of 40 hours at 135-140°C. is typical. The product is readily isolated by
25 quenching the reaction with ice and water, extracting the product into a water immiscible solvent, and evaporation. If desired, the product is further purified by chromatography and/or recrystallization.

30 The starting indolones are available from simple 2(1H,3H)-indolones, suitably substituted on the aromatic ring, by reaction with amides or amide acetals according to Methods A and B. The availability of the starting halides is described above.

Method D - Dealkylation of a Preformed Compound
Containing Aromatic (C₁-C₂)Alkoxy

Compounds of the formula (III) containing an aromatic hydroxy group are preferably prepared by cleavage of the corresponding (C₁-C₂)alkoxy derivatives, most preferably from the corresponding methoxy derivative. A reagent particularly selective for this purpose is boron tribromide, used in excess (e.g., 3 moles/mole of substrate), in a reaction-inert solvent, e.g., methylene chloride. The reagents are usually combined at low temperature (-50 to -100°C., conveniently -78°C., the temperature of a dry ice-acetone bath and then allowed to warm to ambient temperature (e.g., over 2 hours at 25°C.), then quenched into water with brief stirring (e.g., 15 minutes at 25°C.). Acidification, extraction into a water immiscible solvent and evaporation provides a convenient isolation of the product. If desired the product is further purified by chromatography and/or recrystallization.

Method E - Alkylation of a Preformed Compound
Containing a Phenolic Group

Compounds of the formula (III) containing a (C₁-C₂)alkoxy group are alternatively prepared by reaction of an alkylating agent (e.g., ethyl iodide, dimethyl sulfate) with a preformed compound of the formula (III) containing a phenolic group. The phenol is generally alkylated with an excess of alkylating agent (assuring complete reaction in a reasonable time period) in a reaction-inert solvent, in the presence of an excess of an insoluble base such as K₂CO₃ which takes up the acid produced in the alkylation, at 50-100°C.

Method F - Replacement of the Amino Function in an
Aminoalkylidene Derivative with a
Second Amino Function

5 Compounds of the formula (III) wherein the group
-NB¹C¹ is an amino group (open chain or cyclic) are
conveniently prepared by replacement of a first amine
group by reaction with the second amine present in
four or more molar excess. The reaction is carried
out in a reaction-inert solvent, such as ethanol, con-
10 veniently at ambient temperature (15-30°C.) until the
reaction is substantially complete (e.g., 16 hours at
25°C.) and products recovered by simple evaporation in
vacuo, with optional purification by chromatography
and/or recrystallization. This method is a preferred
15 route for preparing compounds of the formulae (I),
(II) or (III) containing a primary amino or cyclic
secondary amino function. The preferred precursors
are 3-(1-dimethylaminoalkylidene) derivatives, readily
available according to Method A.

20 Method G - Replacement of the Hydroxy Function
in a Hydroxyalkylidene Group with
an Amine Function

The preferred route to compounds of the formulae
(I), (II) or (III) containing a imidazolealkylidene
25 group is to react the corresponding hydroxyalkylidene
derivative with carbonyldiimidazole (1-1.1 molar
equivalents) in a reaction inert solvent such as
benzene or toluene, conveniently at ambient tempera-
ture (15-30°C.). Such products generally crystallize
30 directly from the exemplified solvents (benzene or
toluene); but are otherwise recovered by evaporation
with optional purification by chromatography and/or
recrystallization.

-15-

The required hydroxymethylene and 1-hydroxy-ethylidene starting materials are readily available by standard base catalyzed condensation of formate or acetate ester with the appropriately substituted 1-phenyl-2(1H,3H)-indolone.

Method H - Replacement of Alkoxy Function in an Alkoxyalkylidene Group with an Amino Function

Compounds of the formula (III) wherein the group $\text{-NB}^1\text{C}^1$ is an amino group are also conveniently prepared by replacement of an $(\text{C}_1\text{-C}_2)$ alkoxy function in a 1-phenyl-3-(1-alkoxyalkylidene)-2(1H,3H)-indolone, suitably substituted on aromatic rings, using conditions otherwise analogous to those of Method F.

The required 3-(1-alkoxyalkylidene) precursors are obtained by condensation of orthoformate or orthoacetate with the appropriate 1-phenyl-2(1H,3H)-indolone (see Preparation M5, below), in turn available by methods described above.

The clinical utility of the novel compounds of the present invention in the treatment of individuals suffering from schizophrenia is reflected by their potent gabaergic activity. Gabaergic activity refers to the gamma-aminobutyric acid like activity of these compounds in inhibiting convulsions induced by 3-mercaptopropionic acid in an animal model (see for example Roberts and Taberner, Brit. J. Pharmacol. 61:476P, 1977; Adcock and Taberner, Biochem. Pharmacol. 27:246; 1978). Subjects in the present test were Charles-River male mice, Swiss CD strain, 17-21 g., fasted for 18 hours prior to testing. Compounds were administered subcutaneously or orally in a vehicle consisting of 5% ethanol, 5% emulphor 620 and 90% saline, which vehicle alone served as a control

treatment. Compounds were tested on a $.5 \times \log_{10}$ dosage continuum, if active, to achieve data for determination of an ED_{50} value. Solution concentrations were varied at different doses to provide a constant injection volume of 10 ml/kg. The grouped mice were treated with test compounds, and, 1 hour later with 3-mercaptopropionic acid (MPA), 32 mg/kg, intraperitoneally, after which they were observed continuously for 10 minutes. In untreated mice this MPA challenge causes clonic convulsions within 4 minutes of treatment. Protection against MPA convulsions in a given mouse was said to occur if no convulsions occurred during the 10 minute test period. In this test, compounds of the formula (I) showed potent activity. For example, subcutaneous ED_{50} values ranged from 6.6 mg/kg for 1-(3-fluoro-4-methoxyphenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone to about 56 mg/kg for the otherwise corresponding 1-(4-methylphenyl) and 1-(4-methylthiophenyl) analogs. 1-Phenyl-3-(dimethylaminomethylene)-2(1H,3H)-indolone and an extensive number of analogous compounds showed no activity in this test, even at 100 mg/kg. Only a very few compounds of the formula (II) demonstrate such activity, e.g., 1-(3-fluoro-4-methoxyphenyl)-3-(2-pyrrolidinylidene)-2(1H,3H)-indolone; the N-methyl analog thereof; and, in particular, 1-(4-methoxyphenyl)-3-(1-methyl-2-pyrrolidinylidene)-2(1H,3H)-indolone which shows an ED_{50} of 3.2-5.6 mg/kg subcutaneously and 18-32 mg/kg orally.

The clinical utility of novel and known compounds of the present invention [formulae (II) and (III)] in the treatment of hyperanxiety is reflected in their potent in vivo effect on 3H-flunitrazepam (3H-FNP) binding. This effect was measured by the method of

Koe and Weissman, J. Clin. Pharmacol. 21:397S, 1981. Groups of five mice, of the type described above, are injected subcutaneously with 320 micromole/kg of the test compound or vehicle 1 hour prior to an intravenous injection of 200 microCi/kg ^3H -FNP. Twenty minutes after the ^3H -FNP injection, the mice were sacrificed by cervical dislocation, and the brains were removed and immediately frozen. Each brain was weighed quickly and homogenized in 40 volumes (w/v) ice-cold 50 mM Tris HCl pH 7.7 buffer using a Brinkmann Polytron. Triplicate 1.0-ml samples were filtered through Whatman GF/B glass fiber filters under vacuum and washed with two 5 ml aliquots of the ice-cold buffer. The bound ^3H -FNP was measured by adding the filters to vials containing 10 ml. Aquasol-2 and counting the radioactivity. Bound ^3H -FNP for drug-treated mice was calculated as percentage of bound ^3H -FNP for vehicle-treated mice. In this test, compounds of the formula (II) or (III) exhibit enhancement in ^3H -FNP binding, for example, ranging from 126% for 1-(3-chlorophenyl)-3-(morpholinomethylene)-2(1H,3H)-indolone and 1-(3-cyanophenyl)-3-(1-methyl-2-pyrrolidinylidene)-2(1H,3H)-indolone to greater than 250% for the most highly active compounds such as 1-(3-chloro-4-methoxyphenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone and 1-(3-fluoro-4-methoxy)-3-(1-methyl-2-pyrrolidinylidene)-2(1H,3H)-indolone.

In the treatment of a person suffering from schizophrenia (alleviating schizophrenia per se, or reversing or inhibiting the tardive dyskinesia side effects of an earlier or concurrently administered neuroleptic agent) or in the treatment of a person suffering from hyperanxiety, the compounds of the present invention are administered by a variety of

-18-

conventional routes of administration including orally and parenterally. Preferably, the compounds are administered orally, generally in single or multiple daily doses of about 0.02 to 12 mg/kg body weight of the subject to be treated, preferably about 0.05 to 5 mg/kg. If parenteral administration is desired, then these compounds are given in single or multiple daily doses of 0.01 to 6 mg/kg body weight of the subject to be treated. However, at the discretion of the attending physician, there can be some variation in dosage outside of the specified ranges, depending upon the condition of the subject being treated and the particular compound employed.

The compound is administered alone or in combination with pharmaceutically-acceptable carriers or diluents, in either single or multiple doses. Suitable pharmaceutical carriers include inert diluents or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical compositions formed by combining the novel compounds of formula I or salts thereof and pharmaceutically acceptable carriers are readily administered in a variety of dosage forms such as tablets, powders, capsules, lozenges, syrups and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for oral administration, tablets containing various excipients, such as sodium citrate, are employed, together with various disintegrants such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting

purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials therefor include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.

Preferably, the products of this invention are administered orally in unit dosage form i.e., as a single physically discrete dosage unit containing an appropriate amount of the active compound in combination with a pharmaceutically-acceptable carrier or diluent. Examples of such unit dosage forms are tablets or capsules containing from about 1 to 500 mg of the active ingredient, a compound of formulae (I), (II) or (III) comprising from about 10% to 90% of the total weight of the dosage unit.

For parenteral administration, solutions or suspensions of the compounds of formulae (I), (II) or (III) in sterile aqueous solutions, for example aqueous propylene glycol, sodium chloride, dextrose or sodium bicarbonate solutions are employed. Such dosage forms are suitably buffered, if desired. The preparation of suitable sterile liquid media for parenteral administration will be well known to those skilled in the art.

It has been noted that at least one of the compounds of the present invention, viz., 1-(4-methoxyphenyl)-3-(1-methyl-2-pyrrolidinylidene)-2(1H,3H)-indolone, also possesses valuable antidepressant activity, as shown by testing in the antidepressant animal model of Porsolt et al., European J. Pharmacol. 47, pp. 379-391 (1978). It is further noted that the compounds of the present invention possessing the above gabaergic activity are also valuable in the treatment of epilepsy, i.e., in preventing the epileptic seizures associated with that disease. In the treatment of depression, or in the treatment of epilepsy, compounds of the present invention having said antidepressant, or gabaergic activity, respectively, are formulated and administered clinically in the same manner and range of dosage as that disclosed above for the treatment of schizophrenia or hyperanxiety. Based on their excellent gabaergic activity, as well as ease of preparation, preferred compounds for the treatment of epilepsy correspond to those preferred in the treatment of schizophrenia.

The present invention is illustrated by the following examples. However, it should be understood that the invention is not limited to the specific details of these examples. All temperatures are in degrees centigrade.

METHOD AExample A1

1-(3-Chloro-4-methoxyphenyl)-3-(1-dimethyl-
aminoethylidene)-2(1H,3H)-indolone

1-(3-Chloro-4-methoxyphenyl)-2(1H,3H)-indolone (0.67 g, 2.45 mmole), dimethylacetamide dimethylacetal (90%, 0.45 ml, 2.7 mmole) and 10 ml CHCl_3 were refluxed under nitrogen for 3 hours. The reaction mixture was cooled and evaporated in vacuo to a viscous oil. The oil was column chromatographed on silica gel, eluting impurities with ethyl acetate and then product with 2-4% methanol in ethyl acetate, initially isolated as an oil (793 mg). Crystallization from ether gave purified title product, 625 mg, m.p. 138-141°.

Anal. Calcd. for $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}_2\text{Cl}$:

C, 66.56; H, 5.59; N, 8.17; m/e 344/342

Found: C, 66.43; H, 5.34; N, 8.14; m/e 344/342

-22-

EXAMPLE A2

1-Phenyl-3-(1-dimethylaminoethylidene)-
6-chloro-2(1H,3H)-indolone

and

5 1-(3-chlorophenyl)-3-(1-dimethylamino-
 ethylidene-2(1H,3H)-indolone

By the procedure of Example A1, a mixture of
1-(3-chlorophenyl)-2(1H,3H)-indolone and 1-phenyl-6-
chloro-2(1H,3H)-indolone (5.0 g, 0.21 moles) was con-
10 verted to a crude mixture of title products as an oil.
Chromatography on silica gel, using ethyl acetate,
separated and purified the title isomers. The less
polar, faster moving product, was the 3-chlorophenyl
isomer, crystallized from ether, 904 mg, m.p. 113-
15 116°.

Anal. Calcd. for $C_{18}H_{17}N_2OCl$:

C, 69.11; H, 5.48; N, 8.96; m/e 314/312

Found: C, 69.20; H, 5.52; N, 9.08; m/e 314/312

The more polar, slower eluting product was the 6-
20 chloro isomer, an oil which crystallized on standing
and which was triturated with pentane, 0.305 g, m.p.
118-121°.

Anal. Calcd. for $C_{18}H_{17}N_2OCl$:

C, 69.11; H, 5.48; N, 8.96; m/e 314/312

25 Found: C, 68.97; H, 5.47; N, 8.08; m/e 314/312

EXAMPLE A31-(3-Chlorophenyl)-3-(dimethylamino-
methylene)-2(1H,3H)-indolone

By the procedure of Example A1, but substituting an equivalent of dimethylformamide dimethylacetal for the dimethylacetamide dimethylacetal, using first methylene chloride and then 7.5% ethyl acetate in methylene chloride in chromatography and recrystallization from ether-pentane, 1-(3-chlorophenyl)-2(1H,3H)-indolone (10 g, 0.041 mole) was converted to title product, 3.73 g, m.p. 116-118°.

Anal. Calcd. for $C_{17}H_{15}N_2OCl$:

C, 68.34; H, 5.06; N, 9.38

Found: C, 67.99; H, 4.82; N, 9.25

EXAMPLE A41-(3-Fluorophenyl)-3-(dimethylamino-
methylene)-2(1H,3H)-indolone

By the procedure of Example A1, but using 13:7 hexane:ethyl acetate and then 3:7 hexane:ethyl acetate as eluant and ether/pentane for crystallization, 1-(3-fluorophenyl)-2(1H,3H)-indolone (0.80 g, 3.5 mmols) was converted to title product, 0.53 g, m.p. 87-88.5°.

Anal. Calcd. for $C_{17}H_{15}N_2OF \cdot 0.1H_2O$:

C, 71.86; H, 5.39; N, 9.86; m/e 282

Found: C, 71.57; H, 5.10; N, 9.84; m/e 282

EXAMPLE A5

1-(4-Methoxyphenyl)-3-(1-methyl-2-pyrrolidin-ylidene)-2(1H,3H)-indolone

1-(4-Methoxyphenyl)-2(1H,3H)-indolone (49 g,
5 0.205 mole), N-methyl-2-pyrrolidone dimethyl acetal
(ca. 80%, 53 g, 0.245 mole, Ber, 97, pp. 3081-7, 1964)
and 1000 ml chloroform were refluxed under nitrogen
for 1.5 hours. The reaction mixture was cooled and
evaporated in vacuo to solids. Two recrystallizations
10 from ethyl acetate gave purified title product,
44.7 g, m.p. 90-93°C. Thirty grams of this material
were dried at 80°C/15 mm Hg for 20 hours to give 26.1 g
of title product, m.p. 127-9°C.

Anal. Calcd. for $C_{20}H_{20}N_2O_2$:

15 C, 74.97; H, 6.29; N, 8.75; m/e 320

Found: C, 74.99; H, 6.29; N, 8.59; m/e 320

EXAMPLES A6-A10

Method A (Examples A1-A5) was further employed to prepare the following additional compounds.

Listed in sequence are: example number; name of product; name of starting materials; chromatography eluant; crystallization solvent(s); yield; m.p.; C, H and N microanalysis (calculated) found.

A6. 5-Fluoro-1-(4-fluorophenyl)-3-(dimethylamino-methylene)-2(1H,3H)-indolone; 5-fluoro-1-(4-fluorophenyl)-2(1H,3H)-indolone/dimethylformamide dimethylacetal; no chromatography; ether/CH₂Cl₂; 63%; 149-151; (66.98) 66.76, (4.80) 4.50, (9.19) 9.12 for 0.25 H₂O.

A7. 6-Fluoro-1-phenyl-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 6-fluoro-1-phenyl-2(1H,3H)-indolone/dimethylformamide dimethylacetal; no chromatography; ethyl acetate/hexane; 76%; 155-157.5°; (71.18) 71.10, (5.45) 5.49, (9.77) 10.12 for 0.25 H₂O.

A8. 6-Chloro-1-phenyl-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 6-chloro-1-phenyl-2(1H,3H)-indolone/dimethylformamide dimethylacetal; ethyl acetate/hexane; benzene/pentane; 18%; 148-151°; (68.34) 68.69, (5.06) 5.22, (9.38) 9.71.

A9. 1-(3-Fluoro-4-methoxyphenyl)-3-(1-dimethylamino-ethylidene)-2(1H,3H)-indolone; 1-(3-fluoro-4-methoxyphenyl)-2(1H,3H)-indolone/dimethylacetamide dimethylacetal; ethyl acetate; ether; 48%; 187-189°; (69.92) 69.73, (5.87) 6.06, (8.59) 8.40.

A10. 1-(4-Methoxyphenyl)-3-(1-dimethylaminoethylidene)-2(1H,3H)-indolone; 1-(4-methoxyphenyl)-2(1H,3H)-indolone/dimethylacetamide dimethylacetal; ethyl acetate; ether; 66%; 176-177.5°; (74.00) 73.81; (6.54) 6.43; (9.09) 8.79.

PREPARATION A113-(Dimethylaminomethylene)-2(1H,3H)-indolone

2-(1H,3H)-indolone (oxindole, 50 g, 0.376 mole), dimethylformamide dimethylacetal (50 ml, 0.376 mole) and CHCl_3 (300 ml) were combined and refluxed for 6 hours. The reaction mixture was concentrated in vacuo to 150 ml and title product recovered by filtration, 59.5 g, m.p. 192-197°. A second crop was obtained from mother liquor, 6.9 g, m.p. 193-196°. See Ber. 85:774-779 (1952) and Chem. Pharm. Bull. 23:1436-1439 (1975).

Additional preparations by Method A (no chromatography or recrystallization):

A12. 3-[1-(Dimethylamino)ethylidene]-2(1H,3H)-indolone; oxindole/dimethylacetamide dimethylacetal; 87%; 204-207°.

A13. 4-Chloro-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 4-chlorooxindole/dimethylformamide dimethylacetal; 82%; 220-223°.

A14. 6-Chloro-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 6-chlorooxindole/dimethylformamide dimethylacetal; 100%; 224-226°.

A15. 7-Chloro-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 7-chlorooxindole/dimethylformamide dimethylacetal; 70%; 230-232°.

A16. 5-Methoxy-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 5-methoxyoxindole/dimethylformamide dimethylacetal; 66%; 222-225°.

A17. 5-Chloro-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 5-chlorooxindole/dimethylformamide dimethylacetal; 67%; 204-206°.

-27-

METHOD BEXAMPLE B11-(3-Chlorophenyl)-3-(1-benzyl-2-pyrrolidinyldene)-
2(1H,3H)-indolone

N-benzyl-2-pyrrolidone (1.58 ml, 9.85 mmoles) was combined with 2 ml toluene under N_2 and cooled to 0-5°. $POCl_3$ (0.5 ml, 5.9 mmoles) was added and the mixture stirred 30 minutes. Toluene (3 ml) and 1-(3-chlorophenyl)-2(1H,3H)-indolone (1.2 g, 4.92 mmoles) were added and the stirred reaction mixture warmed to 25° for 30 minutes and then to 70-75° for 18 hours. The reaction mixture was cooled, diluted with 100 ml CH_2Cl_2 , washed with saturated $NaHCO_3$, H_2O and brine, dried and concentrated in vacuo to an oil (2.6 g). The oil was chromatographed on silica gel (45 x 150 mm) using CH_2Cl_2 as eluant, yielding title product, initially an oil which was crystallized from ether/pentane, 1.04 g (53%), m.p. 72-75°.

Anal. Calcd. for $C_{25}H_{21}N_2OCl$:

C, 74.89; H, 5.28; N, 6.99; m/e 402/400

Found: C, 74.75; H, 5.41; N, 6.94; m/e 402/400

EXAMPLE B21-(3-Chlorophenyl)-3-(1-methyl-2-piperidylidene)-
2(1H,3H)-indolone

By the procedure of Example B1, but using 1:1 hexane:ethyl acetate as chromatography eluant and pentane for crystallization, 1-(3-chlorophenyl)-2-(1H,3H)-indolone (2.0 g, 8.2 mmoles) and N-methyl-2-piperidone (1.3 ml, 11.5 mmoles) were converted to title product, 180 mg (6.5%) m.p. 162-165°.

Anal. Calcd. for $C_{20}H_{19}N_2OCl$:

C, 70.90; H, 5.65; N, 8.27; m/e 340/338

Found: C, 70.79; H, 5.73; N, 8.05; m/e 340/338

-28-

EXAMPLE B3

1-(3-Chlorophenyl)-3-(1-methyl-2-pyrrolidinylidene)-
2(1H,3H)-indolone

and

5 6-Chloro-1-phenyl-3-(1-methyl-2-pyrrolidinylidene)-
 2(1H,3H)-indolone

By the procedure of Example B1 a mixture of 1-(3-chlorophenyl)-2(1H,3H)-indolone and 6-chloro-1-phenyl-2(1H,3H)-indolone (1.36 g, 5.56 mmoles) and
10 N-methyl-2-pyrrolidone (0.9 ml, 9.34 mmoles) were converted to a crude mixture of title products, as an oil. The isomers were separated, purified and isolated as solid products by silica gel chromatography, using the same eluant. The 3-chlorophenyl isomer was
15 the faster moving, yield 0.72 g, m.p. 134-137°.

Anal. Calcd. for $C_{19}H_{17}N_2OCl$:

C, 70.25; H, 5.28; N, 8.63; m/e 326/324

Found: C, 70.03; H, 5.26; N, 8.69; m/e 326/324

The more polar component was the 6-chloro isomer,
20 yield 0.10 g, m.p. 177-179°.

Anal. Calcd. for $C_{19}H_{17}N_2OCl$:

C, 70.25; H, 5.28; N, 8.63; m/e 326/324

Found: C, 70.44; H, 5.30; N, 8.26; m/e 326/324

EXAMPLE B41-(3-Chloro-4-methoxyphenyl)-3-(1-methyl-2-pyrrolidinylidene)-2(1H,3H)-indolone

By the procedure of Example B1, except that ethyl acetate was used as eluant and ether to crystallize the product, 1-(3-chloro-4-methoxyphenyl)-2(1H,3H)-indolone (1.05 g, 3.84 mole) and N-methyl-2-pyrrolidone (0.62 ml, 6.42 mmoles) were converted to title product, 0.58 g, m.p. 126-127.5°.

Anal. Calcd. for $C_{20}H_{19}N_2O_2Cl$:

C, 67.69; H, 5.40; N, 7.90; m/e 356/354

Found: C, 67.47; H, 5.47; N, 7.90; m/e 356/354

EXAMPLE B51-(3-Fluoro-4-methoxyphenyl)-3-(1-methyl-2-pyrrolidinylidene)-2(1H,3H)-indolone

By the procedure of Example B5, except to use ethyl acetate as eluant, 1-(3-fluoro-4-methoxyphenyl)-2(1H,3H)-indolone (2.0 g, 7.8 mmoles) and 1-methyl-2-pyrrolidone (1.5 ml, 15.6 mmole) were converted to title product, 0.32 g, m.p. 68-71°.

Anal. Calcd. for $C_{20}H_{19}N_2O_2F$:

C, 70.99; H, 5.66; N, 8.28; m/e 338

Found: C, 70.86; H, 5.85; N, 8.13; m/e 338

EXAMPLES B6-B9

Method B (Examples B1-B5) was further employed to prepare the following additional compounds. Listed in sequence are example number; name of product;
5 starting materials; chromatography eluant; crystallization solvent(s); yield; m.p.; C, H and N microanalyses (calculated) found.

B6. 1-(Chlorophenyl)-3-(N-phenyl-N-methylamino-methylene)-2(1H,3H)-indolone; 1-(3-chlorophenyl)-2(1H,3H)-
10 indolone/N-phenyl-N-methylformamide; 1:1 hexane:ethyl acetate; ether/pentane; 19%; 127-129°; (73.22) 73.26, (4.75) 4.84, (7.77) 7.77.

B7. 1-(3-Chlorophenyl)-3-(N-ethyl-2-pyrrolidinylidene)-2(1H,3H)-indolone; 1-(3-chlorophenyl)-2(1H,3H)-indolone/
15 N-ethyl-2-pyrrolidone; chloroform; ethyl acetate/hexane; 38%; 105-107°; (70.90) 70.96, (5.65) 5.84, (8.27) 8.46.

B8. 1-(3-Chlorophenyl)-3-(N-phenyl-2-pyrrolidinylidene)-2(1H,3H)-indolone; 1-(3-chlorophenyl)-2(1H,3H)-indolone/
20 N-phenyl-2-pyrrolidone; 1:1 ethyl acetate:hexane; ether; 33%; 128-130°; (74.51) 74.53, (4.95) 5.04, (7.24) 7.22.

B9. 4-Chloro-1-phenyl-3-(N-methyl-2-pyrrolidinylidene)-2(1H,3H)-indolone; 4-chloro-1-phenyl-2(1H,3H)-indolone/
25 N-methyl-2-pyrrolidone; ethyl acetate; ether/hexane; 20%; 78-80°; (70.25) 69.89, (5.28) 5.56, (8.63) 8.52.

PREPARATION B103-(1-Methyl-2-pyrrolidinylidene)-
2(1H,3H)-indolone

Under nitrogen, N-methyl-2-pyrrolidone (3 ml) was cooled in an ice-water bath. Phosphorus oxychloride (0.91 ml, 0.01 mole) was added dropwise. After stirring 15 minutes, the bath was removed and 2(1H,3H)-indolone (oxindole, 1.3 g, 0.01 mole) in 3 ml. additional N-methyl-2-pyrrolidone (3 ml) was added dropwise. The temperature rose to 40°C. The reaction mixture was then heated at 80° for 16 hours, cooled and partitioned between ethyl acetate and water. The aqueous layer was washed with fresh ethyl acetate, basified to pH 9 with 6N NaOH and clarified by filtration. The filtrate was extracted with ethyl acetate. The extract was evaporated to dryness and the resulting title product triturated with ethyl acetate, 0.24 g, m.p. 268-271°C. (dec). See Ind. J. Chem. 12:940-942 (1974).

Additional preparations by Method B:

B11. 6-Chloro-3-(1-methyl-2-pyrrolidinylidene)-2-(1H,3H)-indolone; 6-chlorooxindole/1-methyl-2-pyrrolidone; no chromatography; no recrystallization; 50%; 227-229°.

B12. 3-[1-(p-chlorobenzyl)-2-pyrrolidinylidene]-2-(1H,3H)-indolone; oxindole/1-(p-chlorobenzyl)-2-pyrrolidone; no chromatography; methanol/ethyl acetate; 46%; 188-190°.

-32-

METHOD CEXAMPLE C11-(3-Methoxyphenyl)-3-(dimethylaminomethylene)-
2(1H,3H)-indolone

5 In a flame dried flask under nitrogen, sodium
hydride (50% dispersion in oil, 0.96 g, 20 mmoles) was
washed free of oil with hexane. Dry dimethylformamide
(DMF, 50 ml) and 3-(dimethylaminomethylene)-2(1H,3H)-
10 indolone [Chem. Ber. 85:774 (1952); 3.77 g, 20 mmoles]
were added, and the mixture stirred for 30 minutes
(until gas evolution ceased). m-Iodoanisole (9.36 g,
40 mmoles) in 20 ml DMF was added, followed by Cu_2Br_2
(5.74 g, 20 mmoles). The reaction mixture was heated
15 at 120-130° for 40 hours, poured over 300 g of ice,
stirred with 300 ml ether, filtered and the ether
layer separated, dried over MgSO_4 , filtered and con-
centrated to an oil. The oil was chromatographed on
silica gel, using ethyl acetate as eluant and title
20 product initially isolated as an oil, crystallized
from ether, 2.46 g (42%), m.p. 106-108.5° (dec.).

Anal. Calcd. for $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_2$:

C, 73.45; H, 6.16; N, 9.52; m/e 294

Found: C, 73.83; H, 5.95; N, 9.49; m/e 294

EXAMPLE C21-(3-Fluoro-4-methoxyphenyl)-3-(dimethylamino-
methylene)-2(1H,3H)-indolone

By the procedure of Example C1, without chromatography, but directly crystallizing the crude product from ether/pentane, 3-(dimethylaminomethylene)-2-(1H,3H)-indolone (3.77 g, 20 mmoles) and 4-bromo-2-fluoroanisole (4.10 g, 20 mmoles) with NaH (0.96 g of 50% dispersion in oil, 20 mmoles) and Cu_2Br_2 (5.74 g, 20 mmoles), were converted to title product, 0.79 g, m.p. 113-114°.

Anal. Calcd. for $\text{C}_{18}\text{H}_{17}\text{N}_2\text{O}_2\text{F}$:

C, 69.21; H, 5.49; N, 8.97; m/e 312

Found: C, 69.06; H, 5.55; N, 8.95; m/e 312

EXAMPLE C31-(3-Trifluoromethylphenyl)-3-(dimethylamino-
methylene)-2(1H,3H)-indolone

Using the same reagent quantities and the procedure of Example C2, but replacing the anisole with m-trifluoromethylphenyl bromide (7.9 ml, 50 mmoles), title product was prepared, 1.43 g, m.p. 103-106°.

Anal. Calcd. for $\text{C}_{18}\text{H}_{15}\text{N}_2\text{OF}_3$:

C, 65.05; H, 4.55; N, 8.43; m/e 332.

Found: C, 64.97; H, 4.53; N, 8.65; m/e 332.

EXAMPLE C4

1-(3-Methylphenyl)-3-(dimethylamino-
methylene)-2(1H,3H)-indolone

5 Using the same reagent quantities and the pro-
cedure of Example C1, but replacing the iodoanisole
with m-iodotoluene (5.1 ml, 40 mmoles), title product
was prepared. Crystallization was from ether/pentane,
2.1 g, m.p. 105-108°.

Anal. Calcd. for $C_{18}H_{18}N_2O$:

10 C, 77.67; H, 6.52; N, 10.07; m/e 278

Found: C, 77.38; H, 6.46; N, 10.06; m/e 278

EXAMPLE C5

1-(3-Cyanophenyl)-3-(dimethylaminomethylene)-
2(1H,3H)-indolone

15 Using the reagent quantities of Example C1,
substituting 3-bromobenzonitrile (7.3 g, 40 mmoles) for
the m-iodoanisole, 1:1 hexane:ethyl acetate as eluant
in chromatography, and allowing the product to crystal-
lize on standing, title product was otherwise prepared
20 according to the procedure of Example C1, 1.3 g; m.p.
140-143°.

Anal. Calcd. for $C_{18}H_{15}N_3O$:

C, 74.72; H, 5.23; N, 14.52; m/e 289

Found: C, 74.32; H, 5.30; N, 14.43; m/e 289

EXAMPLE C6

1-(3-Methylphenyl)-3-(1-dimethylaminoethylidene)-
2(1H,3H)-indolone

Using a reaction time of 18 hours at reflux and crystallizing the product from hexane after chromatography, 3-(1-dimethylaminoethylidene)-2(1H,3H)-indolone (4.06 g, 20 mmoles) was converted to present title product, 0.45 g, m.p. 96-99°.

Anal. Calcd. for $C_{19}H_{20}N_2O$:

C, 78.05; H, 6.90; N, 9.58; O, 5.47; m/e 292

Found: C, 77.85; H, 6.89; N, 9.57; O, 5.69; m/e 292

EXAMPLE C71-(3-Methoxyphenyl)-3-(1-methyl-2-pyrrolidinylidene)-
2(1H,3H)-indolone

Under N₂, 3-(1-methyl-2-pyrrolidinylidene)-2(1H,3H)-
5 indolone (1.0 g, 5 mmoles) was added portionwise to a
slurry of NaH (50% oil dispersion; 265 mg., 5.5 mmoles)
slurried in 50 ml. dimethylformamide and the mixture
stirred at 25° for 2 hours. Cu₂Br₂ (1.43 g, 5 mmoles)
and then m-bromoanisole (1.9 ml, 15 mmole) were added.
10 The mixture was heated at 130° for 3.5 days, cooled,
poured over ice and ethyl acetate, basified with
NH₄OH and filtered over a pad of diatomaceous earth.
The aqueous layer was separated from the filtrate and
extracted with fresh ethyl acetate. The combined
15 organic layers were back-washed with H₂O, dried over
MgSO₄, treated with activated carbon, evaporated
to dryness and the residue triturated with ether,
and filtered to yield starting material (110 mg).
The ether filtrate was evaporated to an oil and
20 chromatographed on 75 ml. silica gel, eluting with
CHCl₃. Clean product fractions were combined, evapo-
rated to an oil and crystallized from CHCl₃/ether,
320 mg, m.p. 127-129° (dec).

Anal. Calcd. for C₂₀H₂₀O₂N₂:

25 C, 74.98; H, 6.29; N, 8.74; m/e 320

Found: C, 74.87; H, 6.28; N, 8.69; m/e 320

EXAMPLES C8-C42

Method C (Examples C1-C7) was further employed to prepare the following additional compounds. Listed in sequence are: example number; name of product; name of starting materials; chromatography eluant; crystallization solvent(s); yield; m.p.; C, H and N microanalyses (calculated) found.

C8. 1-(3-Chloro-4-methoxyphenyl)-3-(dimethylamino-methylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/2-chloro-4-iodoanisole; ethyl acetate/hexane; benzene/pentane; 38%; 148-151°; (65.75) 66.15, (5.21) 5.26, (8.52) 8.47.

C9. 1-(3-Ethylphenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/3-ethylphenyl iodide; ethyl acetate; ether/pentane; 34%; 112-114°; (78.05) 77.75, (6.90) 6.88, (9.58) 9.53.

C10. 1-(3-Chloro-4-methoxy-5-methylphenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/2-chloro-4-bromo-6-methylanisole; 1:1 ethyl acetate:hexane; ether/pentane; 33%; 147-150°; (66.56) 66.48, (5.59) 5.48, (8.17) 7.91.

C11. 1-(2-Methylphenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/2-iodotoluene; ethyl acetate; hexane, then ether; 10%; 105-107°; (77.67) 77.23, (6.52) 6.44, (10.07) 10.06.

C12. 1-(4-Methoxyphenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/4-bromoanisole; not chromatographed; ether/pentane; 20%; 136-138°; (73.45) 73.49, (6.16) 6.20, (9.52) 9.69.

C13. 1-(2-Chloro-5-trifluoromethylphenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/2-chloro-5-trifluoromethylphenyl iodide; 1:1 ethyl acetate:hexane; 5 ethyl acetate/hexane; 14%; 165-167°; (58.94) 58.91, (3.85) 3.94, (7.64) 7.57.

C14. 1-(3,5-Dichlorophenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/3,5-dichlorophenyl iodide; 10 ethyl acetate; not recrystallized; 72%; 147-149.5°; (61.27) 61.02, (4.23) 4.15, (8.41) 8.57.

C15. 5-Chloro-1-(3-chlorophenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 5-chloro-3-(dimethylaminomethylene)-2(1H,3H)-indolone/3-chlorophenyl 15 bromide; chloroform; not recrystallized; 24%; 165-168°; (61.28) 61.34, (4.24) 4.26, (8.40) 8.32.

C16. 1-(2-Nitrophenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/p-bromonitrobenzene; not chromatographed; 20 ether; 29%; 213-215°; (66.01) 66.04, (4.89) 4.91, (13.59) 13.63.

C17. 1-(3-Bromophenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/m-dibromobenzene; not chromatographed; ether; 25 24%; 118-121°; (59.49) 59.56, (4.41) 4.16, (8.16) 8.06.

C18. 1-(2-Chlorophenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/o-chloriodobenzene; no chromatography; 30 ether/pentane; 12%; 169-171°; (68.34) 67.95, (5.06) 5.30, (9.38) 9.45.

C19. 1-(2,5-Dichlorophenyl)-3-(dimethylamino-
methylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-
2(1H,3H)-indolone/2,5-dichloriodobenzene; ethyl acetate;
ether; 19%; 161-163°; (61.27) 61.13, (4.23) 4.28,
5 (8.41) 8.40.

C20. 1-(3,4-Dichlorophenyl)-3-(dimethylaminomethy-
lene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-
2(1H,3H)-indolone/3,4-dichloriodobenzene; not chroma-
tographed; ether; 28%; 149-151°; (61.27) 61.10, (4.23)
10 4.21, (8.41) 8.33.

C21. 1-(3-Nitrophenyl)-3-(dimethylaminomethylene)-
2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-
indolone/m-iodonitrobenzene; not chromatographed; ethyl
acetate/hexane; 51%; 113-116°; (66.01) 65.90, (4.89)
15 4.92, (13.59) 13.53.

C22. 1-(4-Nitrophenyl)-3-(dimethylaminomethylene)-
2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-
indolone/p-bromonitrobenzene; not chromatographed;
ethyl acetate/hexane; 6%; 189-192°; (64.14) 63.84,
20 (5.07) 4.88, (13.20) 13.18 with 0.5 H₂O.

C23. 1-(3-Formylphenyl)-3-(dimethylaminomethylene)-
2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-
indolone/3-iodobenzaldehyde; ethyl acetate; ether; 18%;
120-122°; (73.95) 73.76, (5.52) 5.66, (9.59) 9.89.

C24. 1-(3,4-Dimethoxyphenyl)-3-(dimethylaminomethy-
lene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-
2(1H,3H)-indolone/3,4-dimethoxyphenyl bromide; not
chromatographed; ether; 6%; 164-167°; (70.35) 70.02,
25 (6.22) 6.06, (8.64) 8.69.

C25. 5-Methoxy-1-(3-chlorophenyl)-3-(dimethylamino-methylene)-2(1H,3H)-indolone; 5-Methoxy-3-(dimethylaminomethylene)-2(1H,3H)-indolone/m-chloriodobenzene; chloroform; methanol/ether; 9%; 128-130°; (65.75)

5 65.27, (5.21) 5.19, (8.52) 8.53.

C26. 1-(3-Dimethylcarbamoylphenyl)-3-(dimethylamino-methylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/m-iodo-N,N-dimethylbenzamide; 1:1 ethyl acetate:hexane; toluene/pentane; 24%; 180.5-183°; (70.67) 70.95, (6.38) 6.18, (12.36) 12.35 with 0.25 H₂O.

10

C27. 4-Chloro-1-(3-chlorophenyl)-3-(dimethylamino-methylene)-2(1H,3H)-indolone; 4-chloro-3-(dimethylaminomethylene)-2(1H,3H)-indolone/m-chloriodobenzene; chloroform; chloroform/ether; 5%; 169-170°; (61.28) 60.99, (4.23) 4.13, (8.40) 8.40.

15

C28. 1-(4-Dimethylaminophenyl)-3-(dimethylamino-methylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/p-bromo-N,N-dimethylaniline; ethyl acetate; ethyl acetate; 32%; 192-195°; (74.24) 73.92, (6.89) 6.84, (13.67) 13.99.

20

C29. 1-(4-Methylphenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/p-bromotoluene; ethyl acetate; benzene/pentane; 23%; 135-137°; (77.67) 77.44, (6.52) 6.54, (10.07) 10.29.

25

C30. 1-(4-Methylthiophenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/p-methylthiophenyl bromide; ethyl acetate; ethyl acetate/pentane; 32%; 144-147°; (69.64) 69.45, (5.84) 5.88, (9.03) 8.85.

30

C31. 6-Chloro-1-(3-chlorophenyl)-3-(dimethylamino-methylene)-2(1H,3H)-indolone; 6-chloro-3-(dimethylaminomethylene)-2(1H,3H)-indolone/m-chloriodobenzene; ethyl acetate; cyclohexane; 2%; 128-130°; (61.28) 61.07, (4.23) 4.25, (8.40) 8.37.

C32. 7-Chloro-1-(3-chlorophenyl)-3-(dimethylamino-methylene)-2(1H,3H)-indolone; 7-chloro-3-(dimethylaminomethylene)-2(1H,3H)-indolone/m-chloriodobenzene; ethyl acetate; methanol/ether; 31%; 172-175°; (61.28) 61.31, (4.23) 4.31, (8.40) 8.32.

C33. 1-(3-Methyl-4-methoxyphenyl)-3-(dimethylamino-methylene)-2(1H,3H)-indolone; 3-(dimethylamino-methylene)-2(1H,3H)-indolone/p-bromo-o-methylanisole; ethyl acetate; benzene/pentane; 18%; 172-174°; (74.00) 74.09, (6.54) 6.61, (9.09) 9.08.

C34. 1-(3-Biphenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 3-(dimethylaminomethylene)-2(1H,3H)-indolone/3-bromobiphenyl; ethyl acetate; ether; 34%; 131-133°; (81.15) 81.55, (5.92) 5.93, (8.23) 8.10.

C35. 1-(5-Chloro-2-methoxyphenyl)-3-(dimethylamino-methylene)-2(1H,3H)-indolone; 3-(dimethylamino-methylene)-2(1H,3H)-indolone/p-chloro-o-bromoanisole; ethyl acetate; ether/benzene; 27%; 161-163°; (65.75) 65.39, (5.21) 5.09, (8.52) 8.39.

C36. 1-(3-Isopropyl-4-methoxyphenyl)-3-(dimethylaminomethylene)-2(1H,3H)-indolone; 3-(dimethylamino-methylene)-2(1H,3H)-indolone/p-bromo-o-isopropylanisole; ethyl acetate; ether/pentane; 7%; 133-136°; (74.97) 74.82, (7.19) 7.23, (8.33) 8.10.

C37. 1-(3-Cyanophenyl)-3-(1-methyl-2-pyrrolidinyli-
dene)-2(1H,3H)-indolone; 3-(1-methyl-2-pyrrolidinyli-
dene)-2(1H,3H)-indolone/m-bromobenzonitrile; CHCl_3 ;
ether/ CHCl_3 ; 16%; 172-174°; (76.17) 75.86, (5.43)
5 5.19, (13.32) 13.43.

C38. 1-(3-Dimethylcarbamoylphenyl)-3-(1-methyl-2-
pyrrolidinyli-dene)-2(1H,3H)indolone; 3-(1-methyl-2-
pyrrolidinyli-dene)-2(1H,3H)-indolone/m-iodo-N,N-di-
methylaniline; CHCl_3 ; ether/ CHCl_3 ; 17%; 170-172°;
10 (72.20) 72.22, (6.47) 6.38, (11.48) 11.38 with
0.25 H_2O :

C39. 6-Chloro-1-(3-chlorophenyl)-3-(1-methyl-2-
pyrrolidinyli-dene)-2(1H,3H)-indolone; 6-chloro-3-
(1-methyl-2-pyrrolidinyli-dene)-2(1H,3H)-indolone/m-
15 chloriodobenzene; CHCl_3 ; ether/cyclohexane; 43%;
103-106°; (63.52) 63.54, (4.49) 4.57, (7.80) 7.86.

C40. 1-(4-Chlorophenyl)-3-(1-methyl-2-pyrrolidinyli-
dene)-2(1H,3H)-indolone; 3-(1-methyl-2-pyrrolidinyli-
dene)-2(1H,3H)-indolone/p-chloriodobenzene; ethyl
20 acetate; no recrystallization; 48%; 174-176°; (70.25)
69.93; (5.28) 5.24, (8.63) 8.52.

C41. 1-(3-Chlorophenyl)-3-[1-(p-chlorobenzyl)-2-
pyrrolidinyli-dene]-2(1H,3H)-indolone; 3-[1-(p-
chlorobenzyl)-2-pyrrolidinyli-dene]-2(1H,3H)-indolone/
25 m-chloriodobenzene; 1:1 ethyl acetate:hexane; ether;
29%; 115-117°; (67.57) 67.67, (4.76) 4.73, (6.30)
6.35 for 0.5 H_2O .

C42. 1-(4-Methoxyphenyl)-3-(1-methyl-2-pyrroli-
dinyli-dene)-2(1H,3H)-indolone; 3-(1-methyl-2-
30 pyrrolidinyli-dene)-2(1H,3H)-indolone/p-bromoaniso-
le; ethyl acetate; ether; 8.7%; 130-132°; (74.97) 74.87,
(6.29) 6.32, (8.75) 8.73.

PREPARATION C431-(3-Fluoro-4-methoxyphenyl)indole

Indole (60 g, 0.51 mole), o-fluoro-p-bromo-anisole (112.2 g, 0.547 mole), K_2CO_3 (76 g, 0.55 mole) and Cu_2Br_2 (14 g) were combined in 600 ml N-methylpyrrolidone and heated at 185-200° for 48 hours, stirring under N_2 . The reaction mixture was cooled, poured into ice and water and extracted several times with ethyl acetate. The combined organic layers were washed with H_2O , then brine, dried over $MgSO_4$, treated with activated carbon, and concentrated to an oil (148 g). A portion of the oil (25 g) was chromatographed on silica gel (7.5 x 18 cm) eluting with 1:9 CH_2Cl_2 :hexane, yielding title product as an oil which crystallized on standing in vacuo overnight, 7.2 g, m.p. 65-67°.

Anal. Calcd. for $C_{15}H_{12}NOF$:

C, 74.67; H, 5.02; N, 5.81; m/e 241.

Found:

C, 75.27; H, 5.22; N, 6.10; m/e 241.

PREPARATION C441-(3-Chloro-4-methoxyphenyl)indole

Indole (14 g, 0.120 mole), *o*-chloro-*p*-iodoanisole (34 g, 0.127 mole), K_2CO_3 (18 g, 0.13 mole) and Cu_2Br_2 (1.0 g) were heated in 200 ml N-methylpyrrolidone at 200° for 24 hours. Crude product was isolated as an oil (27.8 g) as in the preceding preparation then distilled (11.0 g, b.p. 169-196°/0.3 mm) and finally chromatographed on silica gel with 1:1 CH_2Cl_2 :ethyl acetate as eluant, yielding purified title product as the faster moving component as a viscous oil, 5.23 g; ^{1}H nmr/ $CDCl_3$ /delta/TMS: 3.9 (s), 6.6 (d), 6.8-7.7 (m); m/e 259/257

The slower moving component was demethylated title product, 5.0 g; viscous oil; m/e 245/243.

PREPARATION C45Di-(4-fluorophenyl) amine

A mixture of p-fluoroacetanilide (76.5 g, 0.5 mole), 4-bromofluorobenzene (262.5 g, 1.5 mole),
5 K_2CO_3 (76 g, 0.55 mole), Cu_2Br_2 (157.8 g, 0.55 mole) and N-methylpyrrolidone (600 ml) were heated at 175-180°. After allowing low boiling material to
condense off, the mixture was heated at reflux for 7
10 days. The mixture was cooled to 60° and quenched into a mixture of 2 liters H_2O , 600 ml ethylenediamine and 1.2 liters toluene, filtered and the toluene layer separated, back-washed 2 x 600 ml H_2O ,
treated with activated carbon, dried over $MgSO_4$ and
concentrated to oily solids in vacuo. The latter
15 were taken up in 1.5 liters 10% ethanolic KOH, refluxed 18 hours and concentrated in vacuo to an oil. The oil was partitioned between 750 ml H_2O and 750 ml. ether. The water layer was washed 2 x 200 ml
ether. The organic layers were combined, back-washed
20 2 x 200 ml H_2O , treated with activated carbon, dried over $MgSO_4$, reconcentrated to an oil (60.3 g) and distilled to yield purified title product 41.6 g,
b.p. 158-160°/2 mm.

PREPARATION C461-(4-Methoxyphenyl)indole

5 By the method of Preparation C43, p-bromoanisole (140 g, 0.75 mole), indole (60 g, 0.51 mole), K_2CO_3 (75 g, 0.54 mole) and Cu_2Br_2 (28 g, 0.1 mole) were converted to title product, purified by distillation, rather than chromatography, 67.7 g, b.p. 150-160/0.4-0.5 mm, which crystallized on storage in the refrigerator, m.p. 52-54°C.

METHOD DEXAMPLE D11-(3-Hydroxyphenyl)-3-(dimethylaminomethylene)-
2(1H,3H)-indolone

5 Under nitrogen, a solution of title product of
Example C1 (0.468 g, 1.59 mmols) in 5 ml CH_2Cl_2 was
cooled to -78° . Boron tribromide (0.45 ml, 4.77
mmols) was added. After stirring 20 minutes at -78° ,
10 the reaction mixture was allowed to warm to room
temperature, stirred 2 hours, diluted with 25 ml. of
water and then 20 ml CH_2Cl_2 , stirred 15 minutes, and
the pH adjusted to 6-7 with saturated NaHCO_3 . The
aqueous layer was separated and extracted 2 x 25 ml
15 CH_2Cl_2 . The three organic layers were combined, dried
over MgSO_4 , and concentrated to solids in vacuo, 0.402
g. Recrystallization from CH_2Cl_2 /hexane gave purified
title product, 0.320 g, m.p. $200-203^\circ$.

Anal. Calcd. for $\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}_2 \cdot 1/4\text{H}_2\text{O}$:

C, 71.69; H, 5.84; 9.84.

20 Found:

C, 71.77; H, 5.72; 9.78.

EXAMPLE EEXAMPLE E11-(3-Ethoxyphenyl)-3-(dimethylamino-
methylene)-2(1H,3H)-indolone

- 5 Title product of Example D1 (0.28 g, 1.0 mmole) in
2 ml of acetone was stirred under N_2 with Na_2CO_3 (0.21
g, 2 mmoles) for 1 hour. Ethyl iodide (2.28 ml) and
0.5 g Na_2CO_3 were then added. The mixture was refluxed
for 11 hours, cooled, salts removed by filtration and
10 the filtrate stripped of solvent in vacuo. The residue
was chromatographed on silica gel (15 cm x 3.5 cm),
eluting with 1:1 ethyl acetate:hexane. The resulting
oil was crystallized from toluene/pentane to yield
purified title product; 51.5 mg; 17%; m.p. 99-102°.
- 15 Anal. Calcd. for $C_{19}H_{20}N_2O_2$:

C, 74.00; H, 6.54; N, 9.09.

Found: C, 73.88; H, 6.54; N, 8.92.

EXAMPLE E24-Bromo-2-chloro-6-methylanisole

- 20 4-Bromo-2-chloro-6-methylphenol (50 g, 0.225 mole)
and K_2CO_3 (31.8 g, 0.23 mole) were combined in acetone
(300 ml). Dimethyl sulfate (32 ml, 0.34 mole) was
added dropwise and the mixture stirred 22 hours at room
temperature; filtered and concentrated to an oil in
25 vacuo. The oil was taken up in 250 ml ether, washed
2 x 2N NaOH, 1 x saturated $NaHCO_3$, 2 x brine, dried
over $MgSO_4$, reconcentrated to an oil and distilled to
yield purified title product, 42.9 g, b.p. 122-124°/0.9
mm, $pnmr/CDCl_3/\delta/TMS$: 2.3 (s, 3H), 3.8 (s, 3H), 7.3
30 (q, 2H).

METHOD FEXAMPLE F11-(3-Chlorophenyl)-3-(pyrrolidinomethylene)-
2(1H,3H)-indolone

5 Pyrrolidine (0.42 ml, 5.0 mmoles) was added to a solution of the title product of Example A3 (0.3 g, 1.0 mmole) in 10 ml of ethanol. The mixture was stirred 3 hours and then allowed to stand for 16 hours at 25°. The reaction mixture was evaporated to dryness in vacuo.
10 The residue was triturated with ether and filtered with pentane wash to yield purified title product, 0.253 g; m.p. 108-112°.

Anal. Calcd. for $C_{19}H_{17}N_2OCl$:

C, 70.25; H, 5.28; N, 8.63; m/e 326/324

15 Found: C, 70.50; H, 5.36; N, 8.80; m/e 326/324

EXAMPLE F21-(3-Chlorophenyl)-3-(morpholinomethylene)-
2(1H,3H)-indolone

Title product of Example A3 (0.3 g, 1.0 mmole),
20 morpholine (0.45 ml, 5 mmole) and ethanol (10 ml) were combined and stirred 18 hours at 25°. Additional morpholine (2 ml) was added and the mixture refluxed 4 hours. The reaction mixture was evaporated in vacuo to an oil, chromatographed on silica gel (4.5 cm x 18
25 cm) eluting with ethyl acetate, initially isolating purified title product as an oil which crystallized on standing under ether/pentane, 0.27 g; m.p. 130-132.5°C.

Anal. Calcd. for $C_{19}H_{17}N_2O_2Cl$:

C, 66.96; H, 5.03; N, 8.22; m/e 342/340

30 Found: C, 66.62; H, 5.07; N, 8.32; m/e 342/340

EXAMPLE F31-(3-Chlorophenyl)-3-(aminomethylene)-
2(1H,3H)-indolone

Title product of Example A3 (0.3 g, 1 mmole) was stirred with 10 ml of ethanol for 3 minutes and the mixture then perfused with NH_3 for 1 hour at 25° , stirred an additional 16 hours, and concentrated to an oil, which crystallized on standing in vacuo. Trituration with pentane gave purified title product, 0.25 g, m.p. $141-143^\circ$.

Anal. Calcd. for $\text{C}_{15}\text{H}_{11}\text{N}_2\text{OCl} \cdot 1/4\text{H}_2\text{O}$:

C, 65.46; H, 4.21; N, 10.18; m/e 272/270

Found: C, 65.22; H, 4.40; N, 10.29; m/e 272/270

EXAMPLES F4-F10

Method F (Examples F1-F3) was further employed to prepare the following additional compounds. Listed sequentially are: example number; product name; starting materials; chromatography eluant; crystallization solvent(s); yield; m.p.; C, H and N microanalyses (calculated) found.

F4. 1-(3-Chlorophenyl)-3-(benzylaminomethylene)-2(1H,3H)-indolone; title product Example A3/benzyl amine; no chromatography; ethanol; 90%; $97-99^\circ$; (73.32) 73.65, (4.75) 4.94, (7.77) 7.98.

F5. 1-(3-Chlorophenyl)-3-(methylaminomethylene)-2(1H,3H)-indolone; title product Example A3/methylamine; no chromatography; ethanol; 73%; $151.5-153^\circ$; (67.49) 67.75, (4.60) 4.77, (9.84) 9.82.

F6. 1-(3-Chlorophenyl)-3-[(N-methyl-N-benzylamino)-methylenel]-2(1H,3H)-indolone; title product of Example A3/N-methylbenzylamine; ethyl acetate/hexane; ethyl acetate/hexane; 3%; 118-120°; (71.96) 71.70, (5.25) 5.22, (7.30) 7.26 with 0.5 H₂O.

F7. 6-Chloro-1-phenyl-3-(aminoethylidene)-2(1H,3H)-indolone; first title product of Example A2/ammonia; no chromatography; ethanol; 29%; 170-172.5°; (67.49) 67.21, (4.60) 4.62, (9.84) 9.77.

F8. 6-Chloro-1-phenyl-3-pyrrolidinoethylidene-2-(1H,3H)-indolone; first title product of Example A2/pyrrolidine; ethyl acetate; ether/pentane; 28%; 128-131°; (70.89) 70.75, (5.65) 5.65, (8.27) 8.32.

F9. 1-(3-Chlorophenyl)-3-(piperidinomethylene)-2(1H,3H)-indolone; title product of Example A3/piperidine; ethyl acetate/hexane; ethyl acetate/hexane; 62%; 153-155°; (70.89) 70.49, (5.65) 5.72, (8.27) 8.32.

F10. 1-(3-Chlorophenyl)-3-(1-aminoethylidene)-2(1H,3H)-indolone; second title product of Example A2/NH₃; no chromatography; ethanol; 70%; 200-202°; (67.49) 67.37, (4.60) 4.67, (9.84) 9.95.

METHOD GEXAMPLE G11-Phenyl-3-[1-(1-imidazolyl)methylene]-
2(1H,3H)-indolone

5 To 1-phenyl-3-(hydroxymethylene)-2(1H,3H)-indolone
(1.0 g, 4.2 mmoles) suspended in 25 ml benzene was
added carbonyldiimidazole (0.75 g, 4.6 mmoles). The
mixture was stirred 16 hours at room temperature and
title product recovered by filtration, 0.39 g, m.p.
10 158-161°.

Anal. Calcd. for $C_{18}H_{13}N_3O \cdot 0.1/2H_2O$:

C, 72.96; H, 4.76; N, 14.18; m/e 287

Found: C, 72.81; H, 4.71; N, 14.22; m/e 287

EXAMPLE G2

15 1-(3-Chlorophenyl)-3-[1-(1-imidazolyl)-
methylene]-2(1H,3H)-indolone

By the procedure of Example G1, substituting
toluene for benzene, 1-(3-chlorophenyl)-3-(hydroxy-
methylene)-2(1H,3H)-indolone was converted to present
20 title product in 11% yield, m.p. 164-166°.

Anal. Calcd. for $C_{18}H_{12}ClN_3O$:

C, 67.19; H, 3.76; N, 13.06.

Found: C, 67.12; H, 4.04; N, 13.21.

METHOD H

EXAMPLE H1

1-(3-Chlorophenyl)-3-(diethylaminomethylene)-
2(1H,3H)-indolone

5 1-(3-Chlorophenyl)-3-(ethoxymethylene)-2(1H,3H)-
indolone (0.15 g, 0.5 mmole), diethylamine (5 ml,
48 mmole) and ethanol (30 ml) were combined and stir-
red 24 hours at 25°. The reaction mixture was con-
centrated in vacuo to an oil. The oil was taken up in
10 ethyl acetate, washed with H₂O and then brine, dried
over MgSO₄ and evaporated to yield title product which
crystallized on cooling and trituration with ether/
pentane, 96 mg. m.p. 74-75.5°.

Anal. Calcd. for C₁₉H₁₉N₂OCl:

15 C, 69.92; H, 5.86; N, 8.57; m/e 328/326
Found: C, 69.70; H, 5.85; N, 8.63; m/e 328/326

METHOD JPREPARATION J1

1-(3-Chlorophenyl)-2(1H,3H)-indolone;
4-Chloro-1-phenyl-2(1H,3H)-indolone; and
6-Chloro-1-phenyl-2(1H,3H)-indolone

5 N-(3-Chlorophenyl)-alpha-chloroacetanilide (63.1 g) and aluminum chloride (70.2 g) were heated for 15 minutes at 180-200°, cooled to 80°, poured over 500 g ice/250 ml conc. HCl and extracted 3 x 500 ml CH₂Cl₂.
10 The combined organic layers were washed 2 x saturated NaHCO₃ and then 2 x brine, dried over MgSO₄, treated with activated carbon and evaporated in vacuo to solids (54.2 g). The solids were chromatographed on silica gel (7.5 x 30 cm) with 19:1 hexane:ethyl acetate as
15 eluant. Faster moving fractions (8-11) gave the 4-chloro-1-phenyl isomer, 2.6 g, m.p. 87-90°. Middle fractions (13-14) gave the 1-(3-chlorophenyl) isomer, 22.1 g, m.p. 110-112.5°. Fractions (15-18) containing a mixture of 1-(3-chlorophenyl) and 6-chloro-1-phenyl
20 isomer, 19.7 g, were retained for rework or used in further processing e.g., in Example A2. Slowest fractions (19-21) gave pure 6-chloro-1-phenyl isomer, 3.6 g, m.p. 116-118.5°.

PREPARATION J2

1-(3-Fluorophenyl)-2(1H,3H)-indolone; and
6-Fluoro-1-phenyl-2(1H,3H)-indolone

5 A mixture of N-(3-fluorophenyl)-alpha-chloro-
acetanilide (5.3 g, 0.02 mole) and AlCl_3 (5.6 g,
0.042 mole) was heated in an open beaker (internal
temperature 180-190°) until gas evolution ceased.
After 10 minutes additional heating at this tempera-
10 ture, the reaction mixture was treated with ice chips,
yielding a brown gum, and then extracted with ether.
Mixed products were then isolated as an oil from the
organic extract according to the preceding example
(4.7 g), chromatographed on 250 g silica gel with
5:1 hexane:ethyl acetate as eluant, collecting 40 ml
15 fractions. Fractions 90-130 gave the 1-(3-fluoro-
phenyl) isomer, 1.3 g, m.p. 94-96°. Middle
fractions gave mixed isomers; and fractions 170-190
gave the 6-fluoro-1-phenyl isomer, 0.41 g, m.p.
63-67°.

-56-

METHOD KPREPARATION K1N-(3-Chlorophenyl)-alpha-chloroacetanilide

5 N-(3-Chlorophenyl)aniline (25.1 g, 0.123 mole) and
chloroacetyl chloride (19.6 ml, 0.246 mole) were re-
fluxed in toluene (100 ml) for 4 hours, then stripped
of toluene and excess acid chloride in vacuo to yield
an oil which crystallized on scratching. Recrystal-
lization from ethanol/H₂O gave purified title product,
10 32.6 g, m.p. 94-96.5°.

PREPARATION K2N-(3-Fluorophenyl)-alpha-chloroacetanilide

15 N-(3-Fluorophenyl)aniline (7.02 g, 0.0375 mole)
and chloroacetyl chloride (3.3 ml, 0.0412 mole) were
refluxed in benzene (50 ml) for 3 hours, then evapo-
rated in vacuo to solids and the solids triturated with
pentane and ether to yield purified title product,
8.69 g, m.p. 115-117°.

METHOD LPREPARATION L11-(3-Fluoro-4-methoxyphenyl)-2(1H,3H)-indolone

1-(3-Fluoro-4-methoxyphenyl)indole (7.0 g, 0.029 mole), N-chlorosuccinimide (98%, 4.14 g, 0.0304 mole) and CH_2Cl_2 (200 ml) were combined and stirred 2 hours at 25°C, producing a solution which was evaporated in vacuo to a semisolid. The latter was diluted with 120 ml $\text{CH}_3\text{CO}_2\text{H}$ and warmed to 70°. H_3PO_4 (85%, 31.3 ml) was added in one portion, the mixture was refluxed 1 hour, cooled, basified with saturated Na_2CO_3 and extracted 4 x 100 ml ethyl acetate. The organic layers were combined, dried over MgSO_4 , and evaporated in vacuo to solids (7.9 g). Chromatography on silica gel, (7.5 x 15 cm) eluting with CH_2Cl_2 in 1 liter fractions gave, on evaporation of combined fractions 4-13, purified title product, 3.8 g, m.p. 133-136°.

PREPARATION L21-(3-Chloro-4-methoxyphenyl)-2(1H,3H)-indolone

Using 3:2 hexane:ethyl acetate as eluant on chromatography, the procedure of the preceding preparation was used to convert 1-(3-chloro-4-methoxyphenyl)indole (0.93 g) to present title product, 0.71 g, m.p. 165-167°.

-58-

PREPARATION L31-(4-Methoxyphenyl)-2(1H,3H)-indolone

Omitting the final chromatography, but triturating the crude product three times with ether, 1-(4-methoxy-
5 phenyl)indole (18.1 g, 81 mmoles) was converted to title product, 12.0 g, m.p. 115-117°C., $\text{pnmr}/\text{CDCl}_3/\text{TMS}/\delta$: 3.65 (s, 2H), 3.8 (s, 3H), 6.6-7.4 (m, 8H).

MISCELLANEOUS METHODSEXAMPLE M11-(3-Fluoro-4-methoxyphenyl)-3-(2-pyrrolidinylidene)-2(1H,3H)-indolone

5 Title product of Preparation L1 (1.0 g, 3.9
mmoles) and 2-ethoxy-1-pyrroline (1.3 g, 11.7 mmoles,
Chem. Pharm. Bull. 17, pp. 2230-2239, 1969) were
combined in 10 ml toluene and refluxed for 20 hours.
Additional 2-ethoxy-1-pyrroline (2 ml) was added
10 and reflux continued for 2 hours. The reaction mixture
was cooled, diluted with ice water and ethyl acetate,
and the organic layer separated, washed with saturated
NaHCO₃, H₂O and brine, dried over MgSO₄ and evaporated
15 in vacuo to crude title product, solids, 1.5 g. Crude
product was chromatographed on silica gel, 4.5 x 18.0
cm column, with ethyl acetate as eluant monitoring by
tlc. Later fractions, R_f 0.1 (1:1 ethyl acetate:
hexane, were combined, evaporated to solids and re-
crystallized from ethyl acetate to yield purified
20 title product, 0.472 g, m.p. 169-171°C.

Anal. Calcd. for C₁₉H₁₇N₂O₂F:

C, 70.35; H, 5.28; N, 8.64.

Found: C, 70.31; H, 5.52; N, 8.56.

25 A second crop, 0.097 g, m.p. 168-170°C, was
obtained from mother liquor.

The method of Example M1 was further employed
to prepare the following additional compounds. Listed
in sequence are example number; name of product;
starting materials; chromatography eluant; crystal-
30 lization solvent(s); yield; m.p.; C, H and N micro-
analyses (calculated) found.

M2. 1-Phenyl-3-(2-perhydroazepinylidene)-2(1H,3H)-indolone; 1-phenyl-2(1H,3H)-indolone/3,4,5,6-tetrahydro-7-methoxy(2H)azepine; no chromatography; benzene/pentane; 46%; 144-146°; (78.91) 78.59, (6.62) 6.60, (9.21) 9.15.

M3. 1-(3-Chlorophenyl)-3-(2-perhydroazepinylidene)-2(1H,3H)-indolone and 6-chloro-1-(3-chlorophenyl-3-(2-perhydroazepinylidene)-2(1H,3H)-indolone; mixture of 1-(3-chlorophenyl)-2(1H,3H)-indolone and 6-chloro-1-phenyl-2(1H,3H)-indolone/3,4,5,6-tetrahydro-7-methoxy(2H)azepine; ethyl acetate/hexane; no recrystallization; 44% and 9%; 144-146° and 158-161°; (70.89) 71.20 and 70.76; (5.65) 5.60 and 5.56; (8.27) 8.30 and 8.10, respectively.

PREPARATION M4

1-(4-Fluorophenyl)-5-fluoroisatin

Oxalyl chloride (9.62 ml, 0.11 mole) was dissolved in 45 ml CH_2Cl_2 . A solution of di-(4-fluorophenyl)-amine (19.7 g, 0.096 mole) in 145 ml CH_2Cl_2 was added over 15 minutes; the temperature rose from 23° to 28°. After stirring 1 hour, AlCl_3 (40.8 g) was added portionwise over 15 minutes; the temperature rose from 20° to 30°, and was kept less than 30° by cooling. After stirring for 10 minutes, the reaction mixture was added to 250 ml ethyl acetate and 500 ml ice and water (the temperature rose to 30°C). The aqueous layer was washed 2 x 250 ml ethyl acetate. The organic layers were combined, back-washed 1 x 400 ml H_2O , dried over MgSO_4 , evaporated to solids and triturated with 100 ml 1:1 ether:hexane to recover title product, 19.9 g, m.p. 180-190°, tlc Rf 0.55 (1:1 ether:hexane).

PREPARATION M55-Fluoro-1-(4-fluorophenyl)-2(1H,3H)-indolone

5 A mixture of title product of the preceding Preparation (4.8 g) KOH (85%, 3 g), hydrazine hydrate (64%, 50 ml) and diethyleneglycol was stirred and slowly heated to 125° (exothermic reaction was noted during warming to 60°). After stirring 16 hours at 125°, the mixture was heated to 140° for 1 hour, then cooled to 50°, poured into 300 ml H₂O, acidified with conc. HCl, and extracted 2 x with CH₂Cl₂. The 10 organic extracts were combined, dried over MgSO₄ and evaporated in vacuo to a gum. The gum was taken up in ether, a small amount of intermediate 3-hydrazone recovered by filtration, and the filtrate evaporated to yield title product, recrystallized from iso- 15 propanol, 2.79 g; m.p. 135-140°; tlc Rf 0.5 (1:1 ether:hexane); m/e 245.

PREPARATION M61-(3-Chlorophenyl)-3-(ethoxymethylene)-
2(1H,3H)-indolone

1-(3-Chlorophenyl)-2(1H,3H)-indolone (2.4 g, 0.01
5 mole) and triethyl orthoformate (8.3 ml, 0.05 mole)
were combined and heated at $150 \pm 10^\circ$ for 18 hours. An
additional 20 ml of the orthoformate were added and
heating continued 2 hours. The reaction mixture was
cooled to 25° , diluted with ether, washed with H_2O and
10 then brine, dried over $MgSO_4$, concentrated in vacuo to
oily solids, and triturated with pentane to yield
solids (4.2 g). The solids were chromatographed on
silica gel (7.5 x 15 cm) with 4:1 hexane:ethyl acetate
as eluant to yield purified title product, 0.5 g; m.p.
15 $132-134^\circ$; m/e 310/299.

PREPARATION M71-Phenyl-3-(hydroxymethylene)-2(1H,3H)-indolone

Potassium t-butoxide (1.63 g, 14.5 mmols) and 5
ml absolute ethanol were heated to 80° . 1-Phenyl-
20 2(1H,3H)-indolone (2.09 g, 10 mmols) was added,
followed by ethyl formate (1.09 ml, 13.5 mmols). The
mixture was heated 5 minutes, cooled to 25° , and the
nearly solid mass diluted with 50 ml H_2O and crushed
ice, acidified to pH 3 with 3N HCl and title product
25 recovered by filtration, 2.2 g, m.p. $192-195^\circ$; m/e 237.
cf J. Prakt. Chem. 135:345-360 (1932); J. Med. Chem.
8:637 (1965).

PREPARATION M8


1-(3-Chlorophenyl)-3-(hydroxymethylene)-
2(1H,3H)-indolone

By the method of the preceding Example, 1-(3-
5 chlorophenyl)-2(1H,3H)-indolone (1.22 g, 5 mmols)
was converted to title product 1.21 g, m.p. 175-178°C,
m/e 273/271.

-64-

CLAIMS

1. A compound of the formula



wherein: A is hydrogen or methyl;
 R is hydrogen or (C₁-C₂)alkyl;
 X is hydrogen, (C₁-C₂)alkyl; (C₁-C₂)alkoxy,
 (C₁-C₂)alkylthio; chloro, fluoro or trifluoro-
 methyl;
 Y is hydrogen, (C₁-C₂)alkyl, (C₁-C₂)alkoxy
 or (C₁-C₂)alkylthio; and
 Z and Z¹ are each independently hydrogen
 or methyl;

with the provisos that:

at least one of X, Y, Z and Z¹ is other than
 hydrogen; and
 at least one of X and Y is other than (C₁-C₂)-
 alkoxy.

2. A compound of claim 1 wherein Z¹ and Z are
 hydrogen.


3. A compound of claim 2 wherein X is chloro
 and Y is hydrogen.

4. The compound of claim 3 wherein both A and
 R are methyl.

5. A pharmaceutical composition suitable for the treatment of a person suffering from schizophrenia which comprises a pharmaceutically-acceptable carrier and a compound of claim 1 in an amount which will alleviate said schizophrenia or reverse the side effects of a neuroleptic agent simultaneously or previously used in the treatment of said schizophrenia.

6. A pharmaceutical composition suitable for treating a person suffering from epileptic seizures which comprises a pharmaceutical carrier and an epileptic seizure preventing amount of a compound of claim 1.

7. A compound of the formula



wherein,

in a first alternative,

A^1 is hydrogen or methyl; and B and C together with the nitrogen atom to which they are attached form a piperidine, pyrrolidine, morpholine or imidazole ring; or

in a second alternative,

A^1 and B together are 1,3-propylene, 1,4-butylene or 1,5-pentylene; and C is hydrogen, (C_1-C_2) alkyl, phenyl or benzyl;

W is hydrogen, (C₁-C₂)alkyl, (C₁-C₂)alkoxy, chloro, or fluoro; and

W¹, X¹ and Y¹ are each independently hydrogen, (C₁-C₂)alkyl, (C₁-C₂)alkoxy, (C₁-C₂)alkylthio, bromo, chloro, fluoro, trifluoromethyl, hydroxy, formyl, carboxamido, (C₁-C₂)alkylcarboxamido, di-(C₁-C₂)alkylcarboxamido, cyano, nitro, amino, (C₁-C₂)alkylamino or di(C₁-C₂)alkylamino.

8. A compound of claim 7 wherein A¹, B and C are in the first alternative.

9. A compound of claim 7 wherein A¹, B and C are in the second alternative.


10. The compound of claim 9 wherein A¹ and B together are 1,3-propylene, C is methyl, W¹, W and X¹ are hydrogen and Y¹ is 4-methoxy.

11. A pharmaceutical composition suitable for treating a person suffering from schizophrenia which comprises a pharmaceutical carrier and the compound of claim 10 in an amount sufficient to alleviate said schizophrenia or reverse the side effects of a neuroleptic agent simultaneously or previously used in the treatment of said schizophrenia.

12. A pharmaceutical composition suitable for treating a person suffering from depression which comprises a pharmaceutical carrier and the compound of claim 10 in an amount sufficient to alleviate said depression.

13. A pharmaceutical composition suitable for treating a person suffering from epileptic seizures which comprises a pharmaceutical carrier and an epileptic seizure preventing amount of the compound of claim 10.

14. A pharmaceutical composition suitable for treating anxiety in a hyperanxious person which comprises a pharmaceutical carrier and an anxiolytic amount of a compound of the formula



wherein,

in a first alternative,

A^2 is hydrogen or methyl, and B^1 and C^1 are each independently hydrogen, (C_1-C_2) -alkyl, phenyl or benzyl;

in a second alternative,

A^2 is hydrogen or methyl, and B^1 and C^1 together with the nitrogen atom to which they are attached form a piperidine, pyrrolidine, morpholine or imidazole ring;

in a third alternative,

A^2 and B^1 together are 1,3-propylene, 1,4-butylene or 1,5-pentylene, and C^1 is hydrogen, (C_1-C_2) alkyl, phenyl or benzyl;

W is hydrogen, (C_1-C_2) alkyl, (C_1-C_2) alkoxy, chloro or fluoro;

W^1 , X^1 and Y^1 are each independently hydrogen, (C_1-C_2) alkyl, (C_1-C_2) alkoxy, (C_1-C_2) alkylthio, bromo, chloro, fluoro, trifluoromethyl, hydroxy, formyl, carboxamido, (C_1-C_2) alkylcarboxamido, di- (C_1-C_2) alkylcarboxamido, cyano, nitro, amino, (C_1-C_2) -alkylamino or di (C_1-C_2) alkylamino;


with the proviso that when A^2 is hydrogen or methyl, B^1 and C^1 are each independently hydrogen, (C_1-C_2) alkyl, phenyl or benzyl, and any one of W^1 , X^1 and Y^1 is 4-chloro, at least one of W^1 , X^1 and Y^1 is other than hydrogen.

15. A compound of the formula III as defined in claim 14 for use as a therapeutic agent, especially for treating anxiety in a hyperanxious person.

-64- (8)

CLAIMS FOR THE CONTRACTING STATE: AT

1. A process for the preparation of a compound of the formula



---(I)

wherein,

in a first alternative,

A^2 is hydrogen or methyl, and B^1 and C^1 are each independently hydrogen, (C_1-C_2) -alkyl, phenyl or benzyl;

in a second alternative,

A^2 is hydrogen or methyl, and B^1 and C^1 together with the nitrogen atom to which they are attached form a piperidine, pyrrolidine, morpholine or imidazole ring;

in a third alternative,

A^2 and B^1 together are 1,3-propylene, 1,4-butylene or 1,5-pentylene, and C^1 is hydrogen, (C_1-C_2) alkyl, phenyl or benzyl;


W is hydrogen, (C_1-C_2) alkyl, (C_1-C_2) alkoxy, chloro or fluoro;

W^1 , X^1 and Y^1 are each independently hydrogen, (C_1-C_2) alkyl, (C_1-C_2) alkoxy, (C_1-C_2) alkylthio, bromo, chloro, fluoro, trifluoromethyl, hydroxy, formyl, carboxamido, (C_1-C_2) alkylcarboxamido, di- (C_1-C_2) alkylcarboxamido, cyano, nitro, amino, (C_1-C_2) alkylamino or di- (C_1-C_2) alkylamino;

-65-(A)


with the provisos that (i) when A^2 is hydrogen or methyl, B^1 and C^1 are each independently hydrogen, (C_1-C_2) alkyl, phenyl or benzyl, and any one of W^1 , X^1 and Y^1 is 4-chloro; at least one of W^1 , X^1 and Y^1 is other than hydrogen; and (ii) when A^2 is hydrogen or methyl, and B^1 and C^1 are the same and are both hydrogen or (C_1-C_2) alkyl, at least one of W^1 , X^1 and Y^1 is other than hydrogen; which is characterized by:

(a) reaction of an amide of the formula



---(II)

wherein A^2 , B^1 and C^1 are as defined above, which has been activated by reaction with $POCl_3$ at $0-30^\circ C$, optionally in the presence of a reaction-inert diluent, with an indolone of the formula



, ---(III)

wherein W , W^1 , X^1 and Y^1 are as defined above;


-66-(A)

(b) when C^1 is hydrogen, reaction of an iminoether of the formula




wherein R^1 is (C_1-C_2) alkyl and A^2 and B^1 are as defined above; with a compound of the formula (III) in a reaction inert solvent at $75-125^\circ\text{C}$ to form a compound of the formula (I) wherein C^1 is hydrogen.

(c) reaction of an anionic compound of the formula



wherein W, A^2 , B^1 and C^1 are as defined above with a phenyl halide of the formula




-67-(A)

wherein X is iodo or bromo and W^1 , X^1 and Y^1 are as defined above, in the presence of Cu_2Br_2 in a reaction inert solvent;

(d) when X^1 , Y^1 or W^1 is hydroxy, dealkylation of a compound of the formula (I) wherein X^1 , Y^1 or W^1 is (C_1-C_2) alkoxy by the action of BBr_3 in a reaction-inert solvent at -100 to $25^\circ C$ to form a compound of the formula (I) wherein X^1 , Y^1 or W^1 is hydroxy;

(e) when X^1 , Y^1 or W^1 is alkoxy, alkylation of a compound of the formula (I) wherein one of W^1 , X^1 or Y^1 is hydroxy by the action of a (C_1-C_2) alkylating agent in a reaction-inert solvent at $50-100^\circ C$ in the presence of an excess of an insoluble base to form a compound of the formula (I) wherein at least one of W^1 , X^1 or Y^1 is (C_1-C_2) alkoxy;


(f) when the compound of the formula (I) is in the first or second alternative, replacement of a first amine group (open chain or cyclic) by reaction with an excess of amine of the formula



wherein B^1 and C^1 are as defined above in the first or second alternative, in a reaction-inert solvent to form a compound of the formula (I) in the first or second alternative;


(g) when B^1 and C^1 together with the nitrogen atom to which they are attached together form an imidazole ring, the reaction of carbonyldiimidazole with a hydroxyalkylidene of the formula

-68- (A)




wherein A^2 , W , W^1 , X^1 and Y^1 are as defined above in a reaction-inert solvent, to form a compound of the formula (I) wherein B^1 and C^1 are taken together with the nitrogen to which they are attached to form an imidazole ring;

(h) when the compound of the formula (I) is in the first or second alternative, reaction of amine of the formula




as defined in paragraph (f) above with an alkoxy-alkylidene compound of the formula



wherein A^2 , R^1 , W , W^1 , X^1 and Y^1 are as defined above, in a reaction inert solvent; or

-69-(A)

(i) when the compound of the formula (I) is in the first or second alternative and both B^1 and C^1 are other than hydrogen, - the reaction of a compound of the formula



with a compound of the formula (III) in a reaction inert solvent at 50-100°C to form a compound of formula (I) in the first or second alternative wherein B^1 and C^1 are other than hydrogen.

2. A process of claim 1 wherein the compound of the formula (I) is in the first alternative.

3. A process of claim 2 wherein B^1 and C^1 are the same and are hydrogen or (C_1-C_2) alkyl, W is hydrogen, and at least one of W^1 , X^1 and Y^1 is other than 3- (C_1-C_2) alkoxy or 4- (C_1-C_2) alkoxy.

4. A process of claim 3 wherein W^1 and Y^1 are hydrogen and X^1 is 3-chloro.

5. A process of claim 4 wherein A^2 , B^1 and C^1 are methyl.

6. A process of claim 1 in the second alternative.

7. A process of claim 6 wherein A^1 , W, W^1 and Y^1 are hydrogen, X^1 is 3-chloro and B^1 and C^1 together with the nitrogen to which they are attached form a pyrrolidine or a morpholine ring.

8. A process of claim 1 in the third alternative.

0104860

-70- (A)

9. A process of claim 8 wherein A^2 and B^1 together are 1,3-propylene and C^1 is methyl.

10. A process of claim 9 wherein W , W^1 and X^1 are hydrogen and Y^1 is 4-methoxy.



European Patent
Office

EUROPEAN SEARCH REPORT

0104860

Application number

DOCUMENTS CONSIDERED TO BE RELEVANT

EP 83305484.4

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 7)
D, X	BE - A - 849 626 (HOECHST AKTIENGESELLSCHAFT) * Page 7, formula V; page 11, line 25 - page 12, line 4; page 19, lines 7-18 * ---	1, 2	C 07 D 209/34 C 07 D 401/04 C 07 D 403/04 C 07 D 403/06 A 61 K 31/40 A 61 K 31/415
A	DE - A - 1 963 182 (PFIZER CORP.) * Claims 1,10 * ---	1,5,6	A 61 K 31/445 A 61 K 31/535
A	DE - A - 2 048 101 (EISAI CO. LTD.) * Pages 1,2 * ---	1,5,6	
A	AT - B - 326 117 (STERLING DRUG INC.) * Claims 1,2; page 8, lines 5-57 * -----	7,8, 11-13	TECHNICAL FIELDS SEARCHED (Int. Cl. 7) C 07 D 209/00 C 07 D 401/00 C 07 D 403/00
The present search report has been drawn up for all claims			
Place of search VIENNA		Date of completion of the search 02-11-1983	Examiner HERING
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			